By Kashish Tandon (Reuters) -Indian drugmaker Anthem Biosciences' [ANTH.NS] $395 million IPO was fully subscribed on the ...

The Rs 3,395 crore Initial Public Offering (IPO) of Anthem Biosciences, the Bangalore-based contract research, development, ...

Anthem Biosciences' initial share sale received bids for 14,47,66,596 shares, as against 4,40,70,682 shares on offer, according to NSE data, translating into 3.28 times subscription.

With a unique business model rooted in innovation-led drug development services, the company is betting big on global ...

Anthem Biosciences, ₹3,395 crore IPO was fully subscribed by Day 2, with strong interest from non-institutional investors, ...

Among investor categories, Non-Institutional Investors (NIIs) have shown the highest interest, bidding 1.55 times their ...

The mainline issue will close for public subscription on Wednesday, July 16. The basis of allotment of shares is likely to be ...

Anthem ticks all the boxes. But with lofty valuations and limited margin headroom, analysts warn the IPO may not deliver ...

Anthem Biosciences IPO sees 20% GMP premium and strong subscriptions on Day 2; check allotment, listing, and key dates now!

The grey market premium for Anthem Biosciences IPO rose from Rs 116 on Monday to Rs 123, as of 10:32 a.m., according to ...

Anthem Biosciences has launched its IPO on July 14, closing on July 16. The ₹3,395 crore offer is entirely for sale by ...

Anthem Biosciences raised ₹1,016.02 crore from 60 institutional investors ahead of its IPO launch on July 14. The offering, ...